Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

Edith A. Perez, Guillermo Lerzo, Xavier Pivot, Eva Thomas, Linda Vahdat, Linda Bosserman, Patrice Viens, Can Cai, Brian Mullaney, Ronald Peck, Gabriel N. Hortobagyi

Research output: Contribution to journalArticle

306 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer (MBC) resistant to anthracycline, taxane, and capecitabine, in this multicenter, phase II study. Patients and Methods: Patients with measurable disease who had tumor progression while receiving prior anthracycline, taxane, and capecitabine were enrolled. Ixabepilone 40 mg/m 2 monotherapy was administered as a 3-hour intravenous infusion on day 1 of a 21-day cycle. The primary end point was objective response rate (ORR), assessed by an independent radiology facility (IRF). Results: A total of 126 patients were treated and 113 were assessable for response. Patients were heavily pretreated: 88% had received at least two lines of prior chemotherapy in the metastatic setting. IRF-assessed ORR was 11.5% (95% CI, 6.3% to 18.9%) for response-assessable patients. Investigator-assessed ORR for all treated patients was 18.3% (95% CI, 11.9% to 26.1%). Fifty percent of patients achieved stable disease (SD); 14.3% achieved SD ≥ 6 months. Median duration of response and progression-free survival were 5.7 and 3.1 months, respectively. Median overall survival was 8.6 months. Patients received a median of 4.0 treatment cycles (range, one to 16 cycles), and 25% of patients received ≥ eight cycles. Grade 3/4 treatment-related events included peripheral sensory neuropathy (14%), fatigue/asthenia (13%), myalgia (8%), and stomatitis/mucositis (6%). Resolution of grade 3/4 peripheral sensory neuropathy occurred after a median period of 5.4 weeks. Conclusion: Ixabepilone demonstrated clear activity and a manageable safety profile in patients with MBC resistant to anthracycline, taxane, and capecitabine. Responses were durable and notable in patients who had not previously responded to multiple prior therapies.

Original languageEnglish (US)
Pages (from-to)3407-3414
Number of pages8
JournalJournal of Clinical Oncology
Volume25
Issue number23
DOIs
StatePublished - Aug 10 2007

Fingerprint

Anthracyclines
Breast Neoplasms
Safety
Peripheral Nervous System Diseases
Radiology
taxane
ixabepilone
Capecitabine
Asthenia
Stomatitis
Mucositis
Myalgia
Intravenous Infusions
Disease-Free Survival
Fatigue
Therapeutics
Research Personnel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. / Perez, Edith A.; Lerzo, Guillermo; Pivot, Xavier; Thomas, Eva; Vahdat, Linda; Bosserman, Linda; Viens, Patrice; Cai, Can; Mullaney, Brian; Peck, Ronald; Hortobagyi, Gabriel N.

In: Journal of Clinical Oncology, Vol. 25, No. 23, 10.08.2007, p. 3407-3414.

Research output: Contribution to journalArticle

Perez, EA, Lerzo, G, Pivot, X, Thomas, E, Vahdat, L, Bosserman, L, Viens, P, Cai, C, Mullaney, B, Peck, R & Hortobagyi, GN 2007, 'Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine', Journal of Clinical Oncology, vol. 25, no. 23, pp. 3407-3414. https://doi.org/10.1200/JCO.2006.09.3849
Perez, Edith A. ; Lerzo, Guillermo ; Pivot, Xavier ; Thomas, Eva ; Vahdat, Linda ; Bosserman, Linda ; Viens, Patrice ; Cai, Can ; Mullaney, Brian ; Peck, Ronald ; Hortobagyi, Gabriel N. / Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 23. pp. 3407-3414.
@article{0febc093189c4f9a944fce4e63fc70dc,
title = "Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine",
abstract = "Purpose: To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer (MBC) resistant to anthracycline, taxane, and capecitabine, in this multicenter, phase II study. Patients and Methods: Patients with measurable disease who had tumor progression while receiving prior anthracycline, taxane, and capecitabine were enrolled. Ixabepilone 40 mg/m 2 monotherapy was administered as a 3-hour intravenous infusion on day 1 of a 21-day cycle. The primary end point was objective response rate (ORR), assessed by an independent radiology facility (IRF). Results: A total of 126 patients were treated and 113 were assessable for response. Patients were heavily pretreated: 88{\%} had received at least two lines of prior chemotherapy in the metastatic setting. IRF-assessed ORR was 11.5{\%} (95{\%} CI, 6.3{\%} to 18.9{\%}) for response-assessable patients. Investigator-assessed ORR for all treated patients was 18.3{\%} (95{\%} CI, 11.9{\%} to 26.1{\%}). Fifty percent of patients achieved stable disease (SD); 14.3{\%} achieved SD ≥ 6 months. Median duration of response and progression-free survival were 5.7 and 3.1 months, respectively. Median overall survival was 8.6 months. Patients received a median of 4.0 treatment cycles (range, one to 16 cycles), and 25{\%} of patients received ≥ eight cycles. Grade 3/4 treatment-related events included peripheral sensory neuropathy (14{\%}), fatigue/asthenia (13{\%}), myalgia (8{\%}), and stomatitis/mucositis (6{\%}). Resolution of grade 3/4 peripheral sensory neuropathy occurred after a median period of 5.4 weeks. Conclusion: Ixabepilone demonstrated clear activity and a manageable safety profile in patients with MBC resistant to anthracycline, taxane, and capecitabine. Responses were durable and notable in patients who had not previously responded to multiple prior therapies.",
author = "Perez, {Edith A.} and Guillermo Lerzo and Xavier Pivot and Eva Thomas and Linda Vahdat and Linda Bosserman and Patrice Viens and Can Cai and Brian Mullaney and Ronald Peck and Hortobagyi, {Gabriel N.}",
year = "2007",
month = "8",
day = "10",
doi = "10.1200/JCO.2006.09.3849",
language = "English (US)",
volume = "25",
pages = "3407--3414",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "23",

}

TY - JOUR

T1 - Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

AU - Perez, Edith A.

AU - Lerzo, Guillermo

AU - Pivot, Xavier

AU - Thomas, Eva

AU - Vahdat, Linda

AU - Bosserman, Linda

AU - Viens, Patrice

AU - Cai, Can

AU - Mullaney, Brian

AU - Peck, Ronald

AU - Hortobagyi, Gabriel N.

PY - 2007/8/10

Y1 - 2007/8/10

N2 - Purpose: To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer (MBC) resistant to anthracycline, taxane, and capecitabine, in this multicenter, phase II study. Patients and Methods: Patients with measurable disease who had tumor progression while receiving prior anthracycline, taxane, and capecitabine were enrolled. Ixabepilone 40 mg/m 2 monotherapy was administered as a 3-hour intravenous infusion on day 1 of a 21-day cycle. The primary end point was objective response rate (ORR), assessed by an independent radiology facility (IRF). Results: A total of 126 patients were treated and 113 were assessable for response. Patients were heavily pretreated: 88% had received at least two lines of prior chemotherapy in the metastatic setting. IRF-assessed ORR was 11.5% (95% CI, 6.3% to 18.9%) for response-assessable patients. Investigator-assessed ORR for all treated patients was 18.3% (95% CI, 11.9% to 26.1%). Fifty percent of patients achieved stable disease (SD); 14.3% achieved SD ≥ 6 months. Median duration of response and progression-free survival were 5.7 and 3.1 months, respectively. Median overall survival was 8.6 months. Patients received a median of 4.0 treatment cycles (range, one to 16 cycles), and 25% of patients received ≥ eight cycles. Grade 3/4 treatment-related events included peripheral sensory neuropathy (14%), fatigue/asthenia (13%), myalgia (8%), and stomatitis/mucositis (6%). Resolution of grade 3/4 peripheral sensory neuropathy occurred after a median period of 5.4 weeks. Conclusion: Ixabepilone demonstrated clear activity and a manageable safety profile in patients with MBC resistant to anthracycline, taxane, and capecitabine. Responses were durable and notable in patients who had not previously responded to multiple prior therapies.

AB - Purpose: To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer (MBC) resistant to anthracycline, taxane, and capecitabine, in this multicenter, phase II study. Patients and Methods: Patients with measurable disease who had tumor progression while receiving prior anthracycline, taxane, and capecitabine were enrolled. Ixabepilone 40 mg/m 2 monotherapy was administered as a 3-hour intravenous infusion on day 1 of a 21-day cycle. The primary end point was objective response rate (ORR), assessed by an independent radiology facility (IRF). Results: A total of 126 patients were treated and 113 were assessable for response. Patients were heavily pretreated: 88% had received at least two lines of prior chemotherapy in the metastatic setting. IRF-assessed ORR was 11.5% (95% CI, 6.3% to 18.9%) for response-assessable patients. Investigator-assessed ORR for all treated patients was 18.3% (95% CI, 11.9% to 26.1%). Fifty percent of patients achieved stable disease (SD); 14.3% achieved SD ≥ 6 months. Median duration of response and progression-free survival were 5.7 and 3.1 months, respectively. Median overall survival was 8.6 months. Patients received a median of 4.0 treatment cycles (range, one to 16 cycles), and 25% of patients received ≥ eight cycles. Grade 3/4 treatment-related events included peripheral sensory neuropathy (14%), fatigue/asthenia (13%), myalgia (8%), and stomatitis/mucositis (6%). Resolution of grade 3/4 peripheral sensory neuropathy occurred after a median period of 5.4 weeks. Conclusion: Ixabepilone demonstrated clear activity and a manageable safety profile in patients with MBC resistant to anthracycline, taxane, and capecitabine. Responses were durable and notable in patients who had not previously responded to multiple prior therapies.

UR - http://www.scopus.com/inward/record.url?scp=34548157209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548157209&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.09.3849

DO - 10.1200/JCO.2006.09.3849

M3 - Article

C2 - 17606974

AN - SCOPUS:34548157209

VL - 25

SP - 3407

EP - 3414

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 23

ER -